BioStock: Positive data in Spago’s phase IIa endometriosis trial

Spago Nanomedical has announced positive top line data from a clinical phase IIa study in patients with endometriosis. SPAGOPIX-02 study is evaluating the MRI-enhancing effect of the contrast agent pegfosimer manganese. The data confirms that the primary endpoint was met, without compromising safety. BioStock reached out to Spago's Chief Executive Officer Mats Hansen to learn more.

Read the interview with Mats Hansen at biostock.se:

Positive data in Spago’s phase IIa endometriosis trial - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/